Visiongain Report Claims There is Huge Potential Within the $117bn Cancer Immunotherapy Market

LONDON, February 12, 2019 /PRNewswire/ --

Global Cancer Immunotherapy Market Forecast 2019-2029 

Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Hospitals, Cancer Research Centres, Clinics

(Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

The world cancer immunotherapy [https://www.visiongain.com/report/global-cancer-immunotherapy-market-forecast-2019-2029 ] market is expected to grow at a CAGR of 11.4% in the second half of the forecast period. The market reached $63bn in 2018, dominated by the monoclonal antibody segment which held 66% share of the market.

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 194-page report you will receive 110 tables and 93 figures- all unavailable elsewhere.

The 194-page report provides clear detailed insight into the global cancer-treating drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

- Global cancer immunotherapy market forecasts from 2019-2029

- This report also breaks down the revenue forecast for the global cancer immunotherapy market by Technology: - Monoclonal Antibodies - Cytokines & immunomodulators - Others (Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy)

Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.

- This report also breaks down the revenue forecast for the global cancer immunotherapy market by Application: - Lung Cancer - Breast Cancer - Colorectal cancer - Melanoma Cancer - Prostate Cancer - Head & Neck Cancer, - Others (Renal Cell Carcinoma, Cervical, Gastric, Lymphoma)

Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.

- This report also breaks down the revenue forecast for the world cancer immunotherapy market by End-User: - Hospitals - Cancer Research Centers - Clinics

Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.

- This report provides individual revenue forecasts to 2029 for these regional and national markets: - North America: US, Canada, Mexico - South America: Brazil, Argentina, Paraguay, Bolivia, Rest of South America - Europe: The UK, Germany, France, Spain, Italy, Rest of Europe - Asia-Pacific: China, Japan, India, Australia, Thailand, Rest of Asia-Pacific - Rest of World: Middle East, Africa, Other Countries

Each regional market is further broken down by technology, application and end-user. 

- This report discusses trends in the industry and assesses drivers and restraints, as well as opportunities and threats. It also includes porters' five force analysis; threat of new entrants, power of suppliers, power of buyers, rivalry among competitors and threat of substituents.

- Our study discusses the selected leading companies that are the major players in the cancer immunotherapy market: - Adaxic Inc - AstraZeneca - Bayer - Bristol-Myers Squibb (BMS) - Eli Lilly and Co. - Medtronic Plc - Merck & Co., Inc. (Merck) - Novartis - Pfizer - Roche

The report provides overviews of the companies, financial information, product portfolio, pipeline products and recent developments.

Visiongain's study is intended for anyone requiring commercial analyses for the global cancer Immunotherapy market. You find data, trends and predictions.

Buy our report today Global Cancer Immunotherapy Market Forecast 2019-2029 [https://www.visiongain.com/report/global-cancer-immunotherapy-market-forecast-2019-2029 ] : Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Hospitals, Cancer Research Centers, Clinics.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-cancer-immunotherapy-market-forecast-2019-2029/ [https://www.visiongain.com/report/global-cancer-immunotherapy-market-forecast-2019-2029 ]

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.com to discuss any customized research needs you may have.

Abbott Laboratories Adaptimmune Therapeutics plc Admune Therapeutics Aduro Biotech Advaxis Inc. Alcon Amgen Astrazeneca UK Bayer AG Baylis Medical BioInvent International BioNTech AG. Biothera Bristol-Mayers Squibb cCAM Biotherapeutics Ltd. Celgene Dendreon Dragonfly Eli Lilly Endocyte, Inc F. Hoffmann-La Roche Ltd Flexus Biosciences, Inc. Genentech (Roche) Genomic Health, Inc. GlaxoSmithKline Incyte IOmet Pharma Ltd Janssen Biotech, Inc. Medtronic Merck & Co., Inc. Merck Sharp & Dohme Limited Moderna Therapeutics NextCure Novartis AG Novartis Pharms Corp Palobiofarma Pfizer, Inc. Qiagen N.V. Regeneron Pharmaceuticals Inc Sandoz Sellas Teva Pharmaceuticals Limited Valeant Pharmaceuticals international

List of Organizations Mentioned in the Report American Association of Cancer Research American Cancer Society American Institute for Cancer Research Association of American Cancer Institutes Canadian Cancer society Cancer Research Institute CDC China Center for Food and Drug International Exchange (CCFDIE) Chinese American Hematologist and Oncologist Network (CAHON) European Commission FDA Fred Hutchinson Cancer Research Center National Cancer Institute Parker Institute for Cancer Immunotherapy Seattle Cancer Care Alliance Seattle Children's Hospital The German Cancer Research Center University of Chicago University of Washington Medical Center WHO

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com


    Photo: 
    https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg


SOURCE Visiongain